Results 11 to 20 of about 18,251 (231)

Alendronate reduces periosteal microperfusion in vivo [PDF]

Heliyon, 2023
Objectives: Bisphosphonates are known to induce a severe adverse effect known as medication-related osteonecrosis of the jaw (MRONJ). Previous studies have proven the impact of bisphosphonates on microperfusion; therefore, this study aimed to investigate
Danielle N. Kundert, Frank Tavassol, Andreas Kampmann, Nils-Claudius Gellrich, Daniel Lindhorst, Marc M. Precht, Paul Schumann   +6 more
doaj   +2 more sources

The Effect of Once-Weekly 70 Mg Alendronate Versus Once-Daily 10 Mg Alendronate in the Treatment of Postmenopausal Osteoporosis [PDF]

Türk Osteoporoz Dergisi, 2004
The aim of this study was to compare the effect of once-weekly 70 mg alendronate versus once-daily 10 mg alendronate in the treatment of postmenopausal osteoporosis. Sixty-three women with postmenopausal osteoporosis were randomly assigned to two groups.
İlker Çorapçı, Cengiz Öner, Onur Armağan, Yavuz Selim Pehlivan, Funda Taşçıoğlu   +4 more
doaj   +1 more source

Two Years of Alendronate and Calcitonin Treatments for Osteoporosis in Postmenopausal Women - Original Investigation

Türk Osteoporoz Dergisi, 2006
This study was to compare and research the effects of alendronate and calcitonin treatments with 2 years duration in women with postmenopausal osteoporosis.
Gülcan Gürer, Ömer Faruk Şendur, Gülnur Taşçı Bozbaş, Engin Taştaban   +3 more
doaj   +1 more source

Alendronate Prevents Early Periprosthetic Bone Loss in Cementless Total Hip Arthroplasty Better Than Simvastatin

Applied Sciences, 2022
Background and Objectives: Cementless total hip arthroplasty leads to an early periprosthetic bone loss, which can impair the osseointegration process and lead to a femoral implant migration during early weight-bearing.
Dragos Apostu, Daniel Oltean-Dan, Alexandru Mester, Andrei Maxim, Adrian Bogdan Tigu, Horea Rares Ciprian Benea, Dan Cosma, Doina Piciu   +7 more
doaj   +1 more source

Improvement of osteoblast adhesion, viability, and mineralization by restoring the cell cytoskeleton after bisphosphonate discontinuation in vitro [PDF]

Journal of Applied Oral Science
Bisphosphonates are prescribed to treat excessive bone resorption in patients with osteoporosis. However, its use is associated with potential adverse effects such as medication-related osteonecrosis of the jaw, prompting the introduction of the drug ...
Somying PATNTIRAPONG, Chunya CHAMPAKERDSAP, Pichaya MATHAVEECHOTIKUL, Apichaya VATANASILP   +3 more
doaj   +1 more source

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis [PDF]

, 2006
BACKGROUND: Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture. METHODS: We performed a randomized, double-placebo, double-blind clinical trial of 18 months' duration ...
Buskens, E.; id_orcid, Jacobs, J.W.G., Laan, R.F., Laan, R.F.J.M., Oostveen, A.C., Lems, W.F., Dijkmans, B.A., Bruyn, G.A.W., Huisman, A.M., Jacobs, J.W., Hofbauer, L.C., Laet, C.E. de, Algra, A., Dijkmans, B.A.C., de Laet, C.E.D., Bruyn, G.A., Geusens, P.P., de Nijs, R.N., Buskens, E., Bijlsma, J.W., Bijlsma, J.W.J., Geusens, P.P.M.M., Laan, R.F.J., Huisman, A., Nijs, R.N. de, Oostveen, A.C.M., de Nijs, R.N.J.   +26 more
core   +1 more source

Disease-Modifying Potential of Metformin and Alendronate in an Experimental Mouse Model of Osteoarthritis

Biomedicines, 2021
Osteoarthritis (OA) is the most common degenerative joint disease causing progressive damages of the cartilage and subchondral bone, synovial inflammation, and severe pain.
Lyudmila Belenska-Todorova, Sevdalina Nikolova Lambova, Stela Stoyanova, Elenka Georgieva, Tsvetelina Batsalova, Dzhemal Moten, Desislava Kolchakova, Balik Dzhambazov   +7 more
doaj   +1 more source

Supra and subgingival application of antiseptics or antibiotics during periodontal therapy

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases (gingivitis and periodontitis) are characterized by inflammatory processes which arise as a result of disruption of the balance in the oral ecosystem. According to the current S3 level clinical practice guidelines, therapy of patients with periodontitis involves a stepwise approach that includes the control of the patient ...
Elena Figuero, Jorge Serrano, Nicole Birgit Arweiler, Thorsten Mathias Auschill, Ali Gürkan, Gülnur Emingil   +5 more
wiley   +1 more source

Myricitrin: A promising herbal therapy for periodontitis in immunosuppressed status

Saudi Dental Journal, 2023
Background: Periodontitis is a complex chronic inflammatory disease aggravated in immunosuppressed patients. However, adjuvant therapies can alleviate severe inflammation and slow down disease progression.
Heba A. Shawky, Marwa M. Essawy
doaj   +1 more source

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend

Bone Reports, 2019
Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor signaling pathway that favors the stimulation of bone formation. Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing ...
Chad L. Deal, Bruce H. Mitlak, Yamei Wang, Lorraine A. Fitzpatrick, Paul D. Miller   +4 more
doaj   +1 more source